Related Experiment Video

Updated: Oct 3, 2025

Implantation of Fibrin Gel on Mouse Lung to Study Lung-specific Angiogenesis
07:52

Implantation of Fibrin Gel on Mouse Lung to Study Lung-specific Angiogenesis

Published on: December 21, 2014

10.2K

Filgrastim, fibrinolysis, and neovascularization

Darwin Eton1, Guolin Zhou2, Tong-Chuan He3

  • 1Department of Surgery, University of Illinois Chicago, Chicago, Illinois, USA.

Journal of Tissue Engineering and Regenerative Medicine
|February 17, 2022
PubMed

Insights

Filgrastim (a granulocyte colony stimulating factor) combined with a programmed compression pump (PCP) promotes artery recanalization in chronic limb-threatening ischemia (CLTI). This novel treatment induces fibrinolysis and a pro-angiogenic environment, warranting further clinical investigation.

Area of Science:

  • Vascular Biology
  • Regenerative Medicine
  • Ischemia Research

Background:

  • Chronic limb-threatening ischemia (CLTI) presents a significant challenge in vascular medicine.
  • Current treatments for CLTI have limitations, necessitating novel therapeutic approaches.
  • Understanding molecular mechanisms of neovascularization and fibrinolysis is crucial for improving CLTI outcomes.

Purpose of the Study:

  • To investigate the effects of Filgrastim, a granulocyte colony stimulating factor, combined with a programmed compression pump (PCP) on segmental recanalization in CLTI patients.
  • To explore the molecular evidence of fibrinolysis and neovascularization induced by this combined therapy.
  • To assess the safety and efficacy of a novel Filgrastim dosimetry in CLTI.

Main Methods:

  • A comparative study involving CLTI patients treated with PCP alone or with Filgrastim and PCP.
  • Plasma and serum samples were analyzed using Enzyme-Linked Immunosorbent Assay (ELISA) to measure plasmin, fibrin degradation products (FDP), and pro-angiogenic proteins (HGF, MMP-9, VEGF A).
  • Blood draws were conducted at baseline and at specific time points following Filgrastim administration and PCP treatment.

Main Results:

  • Filgrastim administration, independent of PCP, significantly increased plasma concentrations of plasmin (>10-fold) and FDP (>5-fold) after the 5th and 10th doses.
  • Significant increases in pro-angiogenic proteins, including HGF, MMP-9, and VEGF A, were observed.
  • The combined therapy demonstrated fibrinolysis and induced a pro-angiogenic milieu without causing acute hemorrhage.

Conclusions:

  • Filgrastim at a novel dosimetry, in conjunction with PCP, effectively induces fibrinolysis and promotes a pro-angiogenic environment in CLTI patients.
  • This therapeutic strategy shows potential for promoting neovascularization and artery recanalization in chronically ischemic tissues.
  • Further clinical trials are warranted to validate this approach in CLTI and other ischemic conditions.

Keywords:
Filgrastimangiogenesisarteriogenesischronic limb ischemiafibrinolysisneovascularization

More Related Videos

Optimized Fibrin Gel Bead Assay for the Study of Angiogenesis14:14

Optimized Fibrin Gel Bead Assay for the Study of Angiogenesis

Published on: April 29, 2007

32.4K
Author Spotlight: Exploring the Potential of Fat-Derived Stromal Vascular Fraction for Wound Healing05:30

Author Spotlight: Exploring the Potential of Fat-Derived Stromal Vascular Fraction for Wound Healing

Published on: November 17, 2023

744

Related Concept Videos

Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
2.9K
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
7.2K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
43
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
7.5K